BioCentury | Oct 13, 2017
Financial News

Catalent proposes $450M notes offering

...On Oct. 10, drug delivery and development solutions company Catalent Inc. (NYSE:CTLT) said its Catalent Pharma Solutions Inc. subsidiary...
BioCentury | Mar 6, 2017
Clinical News

VAL-1221: Ph I/II started

...to 16 ambulatory and ventilator-free patients with late-onset Pompe’s disease. Valerion is partnered with Catalent’s Catalent Pharma Solutions Inc....
BioCentury | Jan 26, 2015
Company News

Sellas, Catalent Pharma deal

...for the indications. Financial details were not disclosed. Sellas Life Sciences Group , Zurich, Switzerland Catalent Pharma Solutions Inc....
BioCentury | Dec 8, 2014
Company News

Valerion, Catalent deal

...Catalent's Catalent Pharma Solutions Inc. subsidiary and Valerion partnered to develop Valerion's two lead preclinical candidates, VAL-1205 and VAL-1221...
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

...2012 offerings with a debt component: a $350 million debt financing by development services company Catalent Pharma Solutions Inc....
...Basel, Switzerland Biocartis S.A. , Lausanne, Switzerland Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Catalent Pharma Solutions Inc....
...2012 average to $18.5 million. The adjustments would exclude a $350 million debt financing by Catalent Pharma Solutions Inc....
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...steps include designing an agent that inhibits both MTP and ABCA1. Aegerion Pharmaceuticals Inc. and Catalent Pharma Solutions Inc....
BioCentury | May 27, 2013
Finance

Value reality check

...billion, helped by a couple of significant fundraisings, including $350 million in venture debt by Catalent Pharma Solutions Inc....
BioCentury | Apr 15, 2013
Company News

Catalent Pharma, Redwood Bioscience deal

...and support sublicense programs. Catalent declined to provide details, and Redwood could not be reached. Catalent Pharma Solutions Inc....
BioCentury | Jan 14, 2013
Company News

Aegerion sales and marketing update

...of 3,000 potential patients in each of the U.S. and EU territories. Additionally, Aegerion granted Catalent Pharma Solutions Inc....
BioCentury | Dec 17, 2012
Company News

Catalent Pharma, UMN Pharma deal

...help it grow its biosimilars business globally. The companies could not be reached for details. Catalent Pharma Solutions Inc....
Items per page:
1 - 10 of 46
BioCentury | Oct 13, 2017
Financial News

Catalent proposes $450M notes offering

...On Oct. 10, drug delivery and development solutions company Catalent Inc. (NYSE:CTLT) said its Catalent Pharma Solutions Inc. subsidiary...
BioCentury | Mar 6, 2017
Clinical News

VAL-1221: Ph I/II started

...to 16 ambulatory and ventilator-free patients with late-onset Pompe’s disease. Valerion is partnered with Catalent’s Catalent Pharma Solutions Inc....
BioCentury | Jan 26, 2015
Company News

Sellas, Catalent Pharma deal

...for the indications. Financial details were not disclosed. Sellas Life Sciences Group , Zurich, Switzerland Catalent Pharma Solutions Inc....
BioCentury | Dec 8, 2014
Company News

Valerion, Catalent deal

...Catalent's Catalent Pharma Solutions Inc. subsidiary and Valerion partnered to develop Valerion's two lead preclinical candidates, VAL-1205 and VAL-1221...
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

...2012 offerings with a debt component: a $350 million debt financing by development services company Catalent Pharma Solutions Inc....
...Basel, Switzerland Biocartis S.A. , Lausanne, Switzerland Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Catalent Pharma Solutions Inc....
...2012 average to $18.5 million. The adjustments would exclude a $350 million debt financing by Catalent Pharma Solutions Inc....
BioCentury | Oct 10, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...steps include designing an agent that inhibits both MTP and ABCA1. Aegerion Pharmaceuticals Inc. and Catalent Pharma Solutions Inc....
BioCentury | May 27, 2013
Finance

Value reality check

...billion, helped by a couple of significant fundraisings, including $350 million in venture debt by Catalent Pharma Solutions Inc....
BioCentury | Apr 15, 2013
Company News

Catalent Pharma, Redwood Bioscience deal

...and support sublicense programs. Catalent declined to provide details, and Redwood could not be reached. Catalent Pharma Solutions Inc....
BioCentury | Jan 14, 2013
Company News

Aegerion sales and marketing update

...of 3,000 potential patients in each of the U.S. and EU territories. Additionally, Aegerion granted Catalent Pharma Solutions Inc....
BioCentury | Dec 17, 2012
Company News

Catalent Pharma, UMN Pharma deal

...help it grow its biosimilars business globally. The companies could not be reached for details. Catalent Pharma Solutions Inc....
Items per page:
1 - 10 of 46